Shattuck Labs Reports Phase 1 Data for SL-325, Marking Key Catalyst

What happened

Shattuck Labs announced Phase 1 results for its lead DR3 antagonist SL-325, the first human data for the program targeting inflammatory bowel disease. The news follows the company's planned IND filing in Q3-2025 and represents a significant milestone after its pivot from oncology to immunology. While the release highlights safety and PK data, specifics on competitive differentiation versus TL1A ligand blockers remain undisclosed. The company's cash runway of $73M as of year-end 2024 provides near-term funding, but ongoing Nasdaq minimum bid price compliance and reliance on future financing persist. The Phase 1 readout reduces clinical execution risk, yet detailed efficacy signals will be crucial to assess positioning in a crowded TL1A/DR3 field.

Implication

Investors should scrutinize the Phase 1 safety, PK, and any biomarker signals to gauge whether SL-325 offers meaningful differentiation over TL1A-targeted programs from Roche, Merck, and AbbVie. A clean safety profile and favorable PK would support upgrading from WAIT to SPECULATIVE BUY, given the high-value IBD theme and potential for partnering. However, weak or non-differentiated data would maintain the WAIT stance, with focus on future financing and listing compliance.

Thesis delta

The Phase 1 results represent the key catalyst identified in the master report, shifting the investment thesis from pre-data uncertainty to early clinical validation. Previously, the WAIT stance hinged on IND acceptance and initial human data; now that data is available, the focus moves to competitive differentiation and next steps. The thesis evolves from waiting for data to evaluating the quality of that data and its implications for partnering and financing needs.